$-0.09 EPS Expected for Pluristem Therapeutics Inc. (PSTI)

August 14, 2018 - By Bradley Stiles

Pluristem Therapeutics Inc. (NASDAQ:PSTI) LogoInvestors sentiment decreased to 0.92 in Q1 2018. Its down 0.75, from 1.67 in 2017Q4. It dropped, as 8 investors sold Pluristem Therapeutics Inc. shares while 5 reduced holdings. 7 funds opened positions while 5 raised stakes. 3.29 million shares or 11.82% less from 3.73 million shares in 2017Q4 were reported.
Virtu Fincl Limited Liability holds 0% or 16,070 shares in its portfolio. Menora Mivtachim Hldg Limited holds 0.04% of its portfolio in Pluristem Therapeutics Inc. (NASDAQ:PSTI) for 1.00M shares. California Public Employees Retirement Systems owns 181,700 shares. State Street Corporation, a Massachusetts-based fund reported 24,624 shares. Susquehanna Intll Grp Limited Liability Partnership reported 74,235 shares or 0% of all its holdings. Riggs Asset Managment Incorporated holds 1,543 shares or 0% of its portfolio. West Oak Capital Limited Liability Corporation reported 400 shares stake. Van Eck Associate has invested 0% in Pluristem Therapeutics Inc. (NASDAQ:PSTI). Atwood Palmer, a Missouri-based fund reported 33 shares. Tower Rech Capital Ltd Llc (Trc) has invested 0% of its portfolio in Pluristem Therapeutics Inc. (NASDAQ:PSTI). Jacobs Levy Equity Management has 24,200 shares for 0% of their portfolio. Florida-based Raymond James Assocs has invested 0% in Pluristem Therapeutics Inc. (NASDAQ:PSTI). Pnc Fincl Services Grp Inc Inc reported 3,600 shares. Millennium Management Ltd Liability Co accumulated 60,654 shares. Citigroup holds 0% of its portfolio in Pluristem Therapeutics Inc. (NASDAQ:PSTI) for 1,040 shares.

Analysts expect Pluristem Therapeutics Inc. (NASDAQ:PSTI) to report $-0.09 EPS on September, 6.They anticipate $0.02 EPS change or 28.57 % from last quarter’s $-0.07 EPS. After having $-0.01 EPS previously, Pluristem Therapeutics Inc.’s analysts see 800.00 % EPS growth. The stock decreased 0.80% or $0.01 during the last trading session, reaching $1.24. About 213,956 shares traded. Pluristem Therapeutics Inc. (NASDAQ:PSTI) has declined 4.29% since August 14, 2017 and is downtrending. It has underperformed by 16.86% the S&P500.

Pluristem Therapeutics Inc. (NASDAQ:PSTI) Ratings Coverage

Among 2 analysts covering Pluristem (NASDAQ:PSTI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Pluristem had 2 analyst reports since May 11, 2018 according to SRatingsIntel. H.C. Wainwright maintained Pluristem Therapeutics Inc. (NASDAQ:PSTI) on Friday, May 11 with “Buy” rating.

Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics firm in Israel. The company has market cap of $137.48 million. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. It currently has negative earnings. The firm develops PLacental eXpanded cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for femoral neck fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases.

More important recent Pluristem Therapeutics Inc. (NASDAQ:PSTI) news were published by: Nasdaq.com which released: “Pluristem Granted Key Patent in Japan for Treatment of GI Following Acute Radiation Exposure” on July 26, 2018, also Streetinsider.com published article titled: “B.Riley/FBR Starts Pluristem Therapeutics (PSTI) at Buy”, Benzinga.com published: “Pluristem Therapeutics, Rexahn Pharma Are Biotech Winners, B Riley FBR Says In Bullish Initiation” on July 31, 2018. More interesting news about Pluristem Therapeutics Inc. (NASDAQ:PSTI) was released by: Globenewswire.com and their article: “Pluristem Initiates Two Pivotal Phase III Studies in Israel” with publication date: August 08, 2018.

Pluristem Therapeutics Inc. (NASDAQ:PSTI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.